Prescription medicine
Tildrakizumab Brand names: Ilumya
Tildrakizumab (Ilumya) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the tildrakizumab FDA label on DailyMed (effective July 29, 2026); every tildrakizumab label on DailyMed.
Highlights of the record
FDA label of July 29, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageILUMYA ® is indicated for the treatment of moderate-to-severe plaque psoriasis in aduts who are candidates for systemic therapy or phototherapy.
Forms and strengths
- 100 mg/ml
Injection (solution).
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 2,321 through July 30, 2026
What is tildrakizumab used for?
From the label: indications and usageILUMYA ® is indicated for the treatment of moderate-to-severe plaque psoriasis in aduts who are candidates for systemic therapy or phototherapy. ILUMYA is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Conditions named in the indications of tildrakizumab's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Interleukin-23 Antagonist.
Source: FDA drug label (ILUMYA), Sun Pharmaceutical Industries, Inc., effective July 29, 2026 (SPL set c6a322bb-51b9-4f0e-8642-62a9682ffcde), via openFDA; the full label on DailyMed
What does the patient leaflet for tildrakizumab say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about ILUMYA?ILUMYA may cause serious side effects, including: Serious allergic reactions. Get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction: feel faint swelling of your face, eyelids, lips, mouth, tongue or throat skin rash trouble breathing or throat tightness chest tightness Infections. ILUMYA is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with ILUMYA and may treat you for TB before you begin treatment with ILUMYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ILUMYA. Tell your healthcare provider right away if you have an infection or develop symptoms of an infection, including: fever, sweats, or chills cough shortness of breath blood in your phlegm (mucus) muscle aches warm, red, or painful skin or sores on your body different from your psoriasis weight loss diarrhea or stomach pain burning when you urinate or urinating more often than normal See “What are the possible side effects of ILUMYA?” for more information about side effects.
Source: FDA drug label (ILUMYA), Sun Pharmaceutical Industries, Inc., effective July 29, 2026 (SPL set c6a322bb-51b9-4f0e-8642-62a9682ffcde), via openFDA; the full label on DailyMed
Is there a generic for tildrakizumab (Ilumya)?
No generic tildrakizumab is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for tildrakizumab?
The FDA Adverse Event Reporting System holds 2,321 reports that list tildrakizumab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 159 are coded as a death and 92 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as tildrakizumab?
7 other medicines are given the same way (subcutaneous) and in the same FDA class as tildrakizumab or labeled mainly for the same use (psoriasis), the same class first. Psoriasis lists all 38 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Risankizumab | Psoriasis | none listed | $22,774.36 per mL 150 mg/mL pen | No current entry |
| Adalimumab-ryvk | Psoriasis | none listed | $499.12 per unit 40 mg/0.4 mL autoinjector | A presentation being discontinued |
| Bimekizumab | Psoriasis | none listed | $8,073.83 per mL 160 mg/mL autoinjector | No current entry |
| Ixekizumab | Psoriasis | none listed | $7,370.72 per mL 80 mg/mL autoinjector | No current entry |
| Secukinumab | Psoriasis | none listed | $3,946.35 per mL 300 mg dose/2 pens (150 mg/pen) | No current entry |
| Spesolimab | Psoriasis | none listed | n/a | No current entry |
| Brodalumab | Psoriasis | none listed | n/a | No current entry |
Every medicine labeled for the same conditions as tildrakizumab
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to tildrakizumab
- 7 medicines for the same use
- Other interleukin-23 antagonists
- the pharmacologic class, with prices and generics
- Tildrakizumab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other